Fusion Pharmaceuticals Inc.
Clinical trials sponsored by Fusion Pharmaceuticals Inc., explained in plain language.
-
New radioactive drug aims to shrink prostate cancer tumors
Disease control OngoingThis phase II trial tests a new drug called FPI-2265 for men with a hard-to-treat type of advanced prostate cancer. The drug delivers a tiny dose of radiation directly to cancer cells. The main goal is to see if it can lower PSA levels, a marker of cancer activity, in 115 partici…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 11:34 UTC
-
New hope for tough prostate cancer: targeted radiation after other treatments fail
Disease control OngoingThis study tests a new drug, FPI-2265, which delivers targeted radiation to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already had a similar type of radiation treatment. The goal is to find the sa…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 11:34 UTC
-
New drug combo aims to shrink tough prostate tumors
Disease control OngoingThis study tests a new drug combination (FPI-2265 and olaparib) in about 85 men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the treatment can shrink tumors and lower PSA levels by at least 50%. Participant…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 11:33 UTC